Myo-Inositol and Pregnancy-Related Acne: An Emerging Option for Dermatology Care
Have you read this article from the JDD? For dermatologists managing acne vulgaris during pregnancy, treatment choices can be limited by fetal safety concerns and the need to avoid conventional therapies. A new review in the Journal of Drugs in Dermatology takes a closer look at myo-inositol as a potential adjunctive option in this setting, especially for patients with hormonal or metabolic features.
The article reviews evidence spanning randomized trials, systematic reviews, observational studies, and mechanistic data to better define where myo-inositol may fit in dermatologic practice. Across the literature, supplementation has been associated with improvements in acne severity, most notably among patients with PCOS, along with better insulin sensitivity and related metabolic markers. Those findings may be especially relevant in pregnancy [https://jddonline.com/?s=pregnancy], where acne can overlap with endocrine and metabolic changes that complicate management.
The review also places myo-inositol in a broader obstetric context. Reported associations with lower gestational diabetes risk, favorable endothelial and metabolic markers, and improved reproductive outcomes may matter to dermatology clinicians caring for pregnant patients with acne and overlapping systemic concerns. In addition, potential effects on mood and sleep add another layer of interest, given their possible impact on acne burden and quality of life.
Importantly, the authors note a favorable maternal and fetal safety profile in the available evidence, while also emphasizing that acne-specific pregnancy data remain limited. Evidence for topical myo-inositol is still sparse.
For dermatology healthcare professionals looking for practical, pregnancy-compatible acne strategies, this review offers a timely update. Read the full article in JDD to see how myo-inositol may inform future acne management in pregnant patients.
Blog write-up assisted by AI
